SummitTX Capital L.P. Buys 89,097 Shares of Bristol Myers Squibb Company $BMY

Key Points

• SummitTX Capital increased its Bristol Myers Squibb stake by 176.2% in the first quarter, adding 89,097 shares to hold 139,670 shares valued at approximately $8.47 million. Institutional investors collectively own 76.41% of BMY.
• Bristol Myers Squibb exceeded quarterly expectations, reporting $1.58 in EPS versus the $1.42 consensus and $11.49 billion in revenue. The company also maintained its 2026 EPS guidance of $6.05–$6.35.
• The company declared a quarterly dividend of $0.63 per share, equivalent to a 4.1% annualized yield, while advancing new lung-cancer and BMS-986533 drug programs to support future pipeline growth.

SummitTX Capital L.P. increased its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 176.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 139,670 shares of the biopharmaceutical company's stock after acquiring an additional 89,097 shares during the quarter. SummitTX Capital L.P.'s holdings in Bristol Myers Squibb were worth $8,471,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Norges Bank purchased a new position in shares of Bristol Myers Squibb during the 4th quarter valued at $1,947,272,000. AQR Capital Management LLC raised its position in shares of Bristol Myers Squibb by 172.6% in the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company's stock worth $1,391,485,000 after buying an additional 16,332,924 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Bristol Myers Squibb by 47.0% during the fourth quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company's stock valued at $1,321,308,000 after buying an additional 7,837,485 shares during the period. Geode Capital Management LLC grew its position in Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock worth $2,837,026,000 after buying an additional 6,084,046 shares in the last quarter. Finally, Man Group plc grew its position in Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company's stock worth $345,594,000 after buying an additional 5,503,391 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced progress on a new lung cancer combination therapy, advancing the program into Phase 2. That suggests continued pipeline momentum and gives investors another potential long-term growth catalyst. Article Title
• Positive Sentiment: The company also expanded its pipeline with a first-in-human trial for BMS-986533, reinforcing the view that Bristol Myers is still investing in new drug candidates beyond its current blockbuster portfolio. Article Title
• Neutral Sentiment: Multiple previews ahead of Bristol Myers Squibb’s upcoming earnings report point to Wall Street expecting earnings growth and a possible beat, which may be supporting shares ahead of the release. Article Title
• Neutral Sentiment: An analyst note on Bristol Myers Squibb was published, but the headline indicates general commentary rather than a major new thesis change, so the market impact appears limited. Article Title
• Negative Sentiment: Broader healthcare commentary flagged some names to avoid, but Bristol Myers Squibb was not singled out; still, it reflects a mixed sentiment backdrop for the sector rather than a company-specific setback. Article Title

Bristol Myers Squibb Trading Down 0.1%

Shares of BMY opened at $62.05 on Monday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The firm has a market cap of $126.70 billion, a price-to-earnings ratio of 17.43, a PEG ratio of 0.18 and a beta of 0.23. The firm has a 50 day moving average price of $57.49 and a 200-day moving average price of $58.06. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm's quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.34 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be issued a $0.63 dividend. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. Bristol Myers Squibb's payout ratio is currently 70.79%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. UBS Group reissued a "buy" rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Weiss Ratings cut shares of Bristol Myers Squibb from a "hold (c+)" rating to a "hold (c)" rating in a research report on Thursday, July 16th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $54.00 price objective on shares of Bristol Myers Squibb in a report on Monday, July 6th. Bank of America cut their target price on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a "buy" rating for the company in a research report on Friday, July 10th. Finally, Wall Street Zen raised Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research note on Saturday, June 27th. Eight equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $61.25.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.